• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Glaucoma  • Ophthalmological Disorders, Other  • Articles for Residents  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Alan L. Robin, MD; Eric P. Suan, MD; Raymond N. Sjaarda, MD; David G. Callanan, MD; Joseph DeFaller, PhD; for the Alcon Anecortave Acetate for IOP Research Team

Arch Ophthalmol. 2009;127(2):173-178.

Objective  To evaluate the intraocular pressure (IOP)–lowering potential of anecortave acetate (AA) in eyes with steroid-related ocular hypertension inadequately controlled with the maximal tolerated or appropriate medical therapy.

Design  Uncontrolled case series.

Methods  A total of 8 eyes of 7 subjects with medically uncontrolled IOP following intravitreal or sub-Tenon injections of triamcinolone acetonide were included. All received an 0.8-mL anterior juxtascleral depot of 3% AA solution (24 mg) under topical anesthesia. The IOP was assessed weekly for the first month, then monthly for a minimum of 1 year.

Results  The mean baseline IOP was 39.9 mm Hg. After 1 week, the mean IOP decreased 12 mm Hg (29%; P = .005) and by 1 month, the mean IOP had decreased 14.1 mm Hg (34.5%; P = .003) from baseline. Four eyes required surgical intervention despite a decrease in IOP because of markedly elevated initial IOP and the degree of preexisting glaucomatous optic neuropathy. We observed no adverse events.

Conclusions  An anterior juxtascleral depot of AA lowers IOP substantially in some eyes with medically uncontrolled steroid-related ocular hypertension. Further study is warranted to clarify the role of AA in treating this condition as well as other forms of glaucoma.

Author Affiliations: Bloomberg School of Public Health and Wilmer Institute (Dr Robin), Johns Hopkins University; Retina Care Center (Dr Suan); and Retina Specialists, Baltimore, Maryland (Dr Sjaarda); Texas Retina Associates, Dallas (Dr Callanan); and Alcon Research Ltd, Fort Worth, Texas (Dr DeFaller and The Alcon Anecortave Acetate for IOP Research Team).
Deceased.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Suppression of Corticosteroid-Induced Ocular Hypertension in Sheep by Anecortave
Candia et al.
Arch Ophthalmol 2010;128:338-343.
ABSTRACT | FULL TEXT  

Suppression and Reduction of Corticosteroid-Induced Ocular Hypertension by Anecortave in Sheep
Kaufman
Arch Ophthalmol 2010;128:365-366.
FULL TEXT